Literature DB >> 15361205

High-risk endometrial cancer in young indigent women.

A Ben-Arie1, S Perlman, Y Hazan, L A Solomon, C Edwards, A L Kaplan.   

Abstract

OBJECTIVE: The aim of this study was to evaluate a different prevalence and clinical pattern of high-risk endometrial cancer in an indigent population of young women.
METHODS: Charts of 71 consecutive patients, treated for endometrial adenocarcinoma during a 6-year period, were reviewed. The patients were divided into two groups contingent upon age--(i) those who were below 40 years and (ii) those who were over 40. Based on histological type, grade, and stage, both groups were subdivided into a low, intermediate, or high-risk cancer category.
RESULTS: Of the 13 (18.3%) patients in the younger age group, five patients (38.4%) had high-risk endometrial cancer, compared to only eight patients (13.8%) in the older age group.
CONCLUSION: In contradiction to previous reports, our results show that a higher proportion of young indigent women diagnosed with endometrial cancer have a high-risk cancer. Delay in diagnosis can explain only some of the discrepancies in the special clinical pattern of endometrial cancer among this population. Other possible explanations include nutritional differences, genetic susceptibility, immunological status, and high-risk behavior. More epidemiological studies are needed for complete understanding of the unfavorable outcome of endometrial cancer in these young women.

Entities:  

Mesh:

Year:  2004        PMID: 15361205     DOI: 10.1111/j.1048-891X.2004.14531.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  6 in total

1.  Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-survivin pathway.

Authors:  Rujia Fan; Yiying Wang; Yue Wang; Li Wei; Wenxin Zheng
Journal:  Am J Transl Res       Date:  2017-03-15       Impact factor: 4.060

2.  Stigmasterol sensitizes endometrial cancer cells to chemotherapy by repressing Nrf2 signal pathway.

Authors:  Hong Liao; Dan Zhu; Mingzhu Bai; Huifen Chen; Shihuan Yan; Jing Yu; Huiting Zhu; Wenxin Zheng; Guorong Fan
Journal:  Cancer Cell Int       Date:  2020-10-06       Impact factor: 5.722

3.  Characteristics and prognosis of coexisting adnexa malignancy with endometrial cancer: a single institution review of 51 cases.

Authors:  Lu Chen; Qiang Zhao; Xiaojuan Lv
Journal:  Arch Gynecol Obstet       Date:  2010-06-29       Impact factor: 2.344

4.  Isoliquiritigenin induces apoptosis and autophagy and inhibits endometrial cancer growth in mice.

Authors:  Chi-Hao Wu; Hsin-Yuan Chen; Chia-Woei Wang; Tzong-Ming Shieh; Tsui-Chin Huang; Li-Chun Lin; Kai-Lee Wang; Shih-Min Hsia
Journal:  Oncotarget       Date:  2016-11-08

5.  Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-AKR1C1 pathway.

Authors:  Yiying Wang; Yue Wang; Zhenbo Zhang; Ji-Young Park; Donghui Guo; Hong Liao; Xiaofang Yi; Yu Zheng; Donna Zhang; Setsuko K Chambers; Wenxin Zheng
Journal:  Oncotarget       Date:  2016-03-01

6.  Adlay Testa (Coix lachryma-jobi L. var. Ma-yuen Stapf.) Ethanolic Extract and Its Active Components Exert Anti-Proliferative Effects on Endometrial Cancer Cells via Cell Cycle Arrest.

Authors:  Yun-Ju Huang; Chih-Chao Chang; Yun-Ya Wang; Wen-Chang Chiang; Yin-Hwa Shih; Tzong-Ming Shieh; Kai-Lee Wang; Mohamed Ali; Shih-Min Hsia
Journal:  Molecules       Date:  2021-03-31       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.